#4 - Soligenix (NASDAQ:SNGX)
Soligenix Inc. (NASDAQ: SNGX) is a late-stage biopharmaceutical company focusing on developing and commercializing products to treat rare diseases. Like many clinical-stage biopharma companies, Soligenix is a penny stock and is likely to remain that way until, and unless, it can get one of its pipeline candidates across the finish line.
That's where the bullish case exists. The company's lead candidate is HyBryte, a photodynamic topical therapy for treating early-stage cutaneous T-cell lymphoma (CTCL). The company recently completed a Phase 3 trial. It was granted Orphan Drug and Fast Track Designation in the United States, Orphan Drug Designation in Europe and Promising Innovative Medicine designation by the UK Health Authority.
SNGX stock is not heavily covered by analysts. However, the one firm that has issued a rating gives the stock a Strong Buy rating with a $3.00 price target. That would be a gain of over 347%, making Soligenix the very definition of a speculative stock.
About Soligenix
Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease.
Read More - Current Price
- $2.95
- Consensus Rating
- N/A
- Ratings Breakdown
- 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- N/A
